ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
PGR	5241	15555905	-	Up regulation/ Over expression/High expression	-	-	16 normal endometria (6 with proliferative phase and 10 with secretory phase) and 17 endometrial hyperplasias [7 with simple hyperplasia (SH); 4 with complex hyperplasia (CH) and 6 with complex atypical hyperplasia	141	35 to 83	57	Kitasato University Hospital	I (n=89); II (n=18); IIIA (n=16); IIIC (n=11); IV (n=4)	1 (n=76); 2 (n=35); 3 (n=30)	[1] PR-A and -B expressions were significantly correlated with biologically malignant potential. [2] PR-B expression significantly occurred more frequently in G1. It was inversely correlated with p53 gene mutation and p53 over expression; andalso with clinicopathological variables; including myometrial and lymph-vascular space invasion and the FIGO stage. PR-A expression was also significantly higher in G1 and was inversely correlated with Ki-67 expression and myometrial invasion; but not with prognosis. [3] The LIs of PR-A inG1; G2 and G3 endometrial carcinomas were 13.7±24.7%; 13.8±27.7% and 2.4±12.9%; respectively. PR-A expressionin endometrial carcinomas was significantly lower forthe higher histological grade (G1 versus G3; p = 0.0079). The LIs of PR-A in normal endometrium and endometrial hyperplasias were significantly higher than that for allendometrial adenocarcinomas; respectively (p = 0.0153 and<0.0001). The LIs of PR-A in the proliferativephase endometrium and each hyperplasia were significantlyhigher than that forG1adenocarcinoma (p < 0.0001; <0.0001;0.0137; and 0.0001)	Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma.	The Journal of steroid biochemistry and molecular biology	92(3):111-8	2004
PGR	5241	19382201	Endometroid adenocarcinoma	Polymorphism	-	-	1018	1037 (967 adenocarcinoma+ 12 clear cell carcinoma+ 33 other pathologic types+ 13 unknown)	30 to 69	-	Sanghai; China	-	-	[1] Polymorphisms in the 3' flanking region of the PGR gene may be associated with the risk of endometrial cancer. [2] Two polymorphisms in the 3' flanking region of the PGR gene; reference SNP identification number (rs) 11224561 (rs11224561) and rs471767; were associated with the risk of endometrial cancer. The cytosine/cytosine (CC) genotype of SNP rs11224561 was associated with decreased risk (OR; 0.68; 95% CI; 0.50-0.92) compared with the thymine/thymine (TT) genotype. Carrying the guanine (G) allele of the rs471767 SNP also was associated with decreased risk.	Association of the progesterone receptor gene with endometrial cancer risk in a Chinese population.	Cancer	115(12):2693-700	2009
PGR	5241	8104681	Endometrial adenocarcinoma + Papillary Serous carcinoma	-	-	-	-	32 (Endometrial adenocarcinoma) + 2 (Papillary Serous carcinoma)	-	-	-	I (n=17); II (n=4); III (n=13)	1 (n=12); 2 (n=14); 3 (n=6)	[1] In the endometrial carcinomas; PR positivity was found in 24 of the 34 (70.6%). [2] The positivity for ER or PR was observed in 12 of the 17 (70.6%) patients with Stage I disease; 3 of the 4 (75%) patients withStage 11; and 9 of the 13 (69.2%) patients with Stage I11disease. [3] ER or PR positivity also was significantly correlated with histologic differentiation in endometrioid-type carcinomas; ER or PR were positive in 91.7% of G1; 78.6% of G2; and 33.3% of G3 tumors	Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status.	Cancer	72(9):2628-37	1993